98313 20240118091947.0 sideral 122055 ART-2019-122055 eng Cequier, A. Universidad de Zaragoza (orcid)0000-0002-1481-9805 Humoral immune response against allogeneic equine mesenchymal stem cells (MSCs) mediated by the major histocompatibility complex (MHC): an issue to take into account for the safety and efficacy of treatment with MSCs 2019 Access copy available to the general public Unrestricted Allogeneic mesenchymal stem cells (MSCs) present several advantages, but recipient immune response needs to be further elucidated. Proinflammatory priming of MSCs activated their in vivo regulatory capacity, but repeated administrations led to slight inflammatory reaction in an osteoarthritis equine model. This may be associated with higher major histocompatibility complex (MHC) expression, which would increase MSC immunogenicity potentially inducing humoral mediated immune memory. This study aimed at assessing allo-antibody production against donor’s equine MHC (equine leukocyte antigen, ELA) in animals that received intra-articular repeated administration of allogeneic MSC-primed. For this purpose, we used stored samples from a previous study. Donor and recipients ELA-haplotypes were stablished by microsatellite typing and complementmediated microcytoxicity assays were carried out by exposing target cells from the donor (unstimulated MSCs [MSC-nai¨ve], MSC-primed or lymphocytes [control]) to sera collected at different time-points from 10 recipients: ELA-mismatched MSCnai ¨ve recipients, ELA-mismatched MSC-primed recipients or ELA-partially matched MSC-primed recipients. All animals receiving allogeneic MSCs produced allo-antibodies after the first injection, regardless of the matching degree. However, antibody peak production after second administration was only observed in ELA-mismatched recipients, both of MSC-nai¨ve and MSCprimed. Horses injected with MSC-primed produced fewer antibodies but MSC-primed were more targeted in the microcytoxicity assay. Thus, activated immunomodulatory profile of MSC-primed could have led to slighter humoral response after ... info:eu-repo/semantics/openAccess by-nc-nd http://creativecommons.org/licenses/by-nc-nd/3.0/es/ 4.273 2019 BIOTECHNOLOGY & APPLIED MICROBIOLOGY 30 / 156 = 0.192 2019 Q1 T1 GENETICS & HEREDITY 38 / 176 = 0.216 2019 Q1 T1 MEDICINE, RESEARCH & EXPERIMENTAL 40 / 138 = 0.29 2019 Q2 T1 1.648 2019 Genetics 2019 Q1 Molecular Medicine 2019 Q1 Molecular Biology 2019 Q2 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Barrachina, L. Universidad de Zaragoza (orcid)0000-0001-9818-508X Romero, A. Universidad de Zaragoza (orcid)0000-0001-7188-0461 Vitoria, A. Universidad de Zaragoza (orcid)0000-0003-1286-4968 Zaragoza, P. Universidad de Zaragoza (orcid)0000-0001-5740-0185 Vazquez, F.J. Universidad de Zaragoza (orcid)0000-0002-8712-2275 Rodellar, C. Universidad de Zaragoza (orcid)0000-0003-3289-2675 1001 420 Universidad de Zaragoza Dpto. Anatom.,Embri.Genét.Ani. Área Genética 1009 617 Universidad de Zaragoza Dpto. Patología Animal Área Medicina y Cirugía Animal 30, 11 (2019), A164 Hum. gene ther. HUMAN GENE THERAPY 1043-0342 59723 http://zaguan.unizar.es/record/98313/files/texto_completo.pdf Versión publicada 3449429 http://zaguan.unizar.es/record/98313/files/texto_completo.jpg?subformat=icon icon Versión publicada https://www.liebertpub.com/doi/pdf/10.1089/hum.2019.29095.abstracts Texto completo de la revista oai:zaguan.unizar.es:98313 articulos driver 2024-01-18-09:11:49 ARTICLE